Recorded 11/6/2022 This transcript has been edited for clarity.
Robert A. Harrington, MD: Hi. I'm Bob Harrington from Stanford University, here at the American Heart Association (AHA) meeting in Chicago. I'm on theheart.org | Medscape Cardiology.
During the course of many of these interviews over the years, we touch upon a lot of topics. We talk about science, hot topics, or controversial topics in the world of cardiovascular medicine.
Today, I have one that I hope, in particular, my mid-career and senior colleagues will take a careful listen to. I've been intrigued, at this point in my own career, at people making decisions to do something else than what I'll call traditional academic or clinical medicine. What are some of those other things you can do?
At this meeting, I happened to run into two really good friends and close colleagues. I asked them to sit with me for 10 or 15 minutes and talk to me about why they recently made a decision, in this case, to move from academic medicine to industry — one into the technology sector and one into the biopharma sector.
I'm really pleased to be joined today by Mintu Turakhia. Mintu is a professor of medicine at Stanford University.
